MCM
GALT icon

MAI Capital Management’s Galectin Therapeutics GALT Stock Holding History

MAI Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$2.79K – 3085
2026
Q1 		$2.79K Hold
1,000
– – ﹤0.01% 3791
2025
Q4 		$4.16K Hold
1,000
– – ﹤0.01% 3180
2025
Q3 		$4.24K Hold
1,000
– – ﹤0.01% 3080
2025
Q2 		$2.11K Hold
1,000
– – ﹤0.01% 3399
2025
Q1 		$1.22K Hold
1,000
– – ﹤0.01% 3083
2024
Q4 		$1.29K Buy
+1,000
New +$2.4K ﹤0.01% 3129

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MAI Capital Management's GALT Position: Q2 2026 in Review

MAI Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 1,000 shares — an estimated $2.79K sold.

MAI Capital Management first reported a position in GALT in Q4 2024 and held it in 6 quarters. The position peaked at $4.24K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • MAI Capital Management reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,000 Galectin Therapeutics shares in Q2 2026, an estimated $2.79K.
  • MAI Capital Management first reported a position in Galectin Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Galectin Therapeutics position peaked at $4.24K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.